

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	2
INTENDED AUDIENCE.....	2
SCOPE OF REPORT.....	3
METHODOLOGY.....	3
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER.....	4
 CHAPTER TWO: SUMMARY.....	 5
SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2009 AND 2014 (\$ MILLIONS)</i>	6
 CHAPTER THREE: OVERVIEW.....	 7
HISTORY AND CURRENT STATE OF ANTIFUNGALS.....	7
TYPES OF PATHOGENIC FUNGI.....	8
DEFINITION OF THE INDUSTRY.....	8
CONCEPTS IN THE INDUSTRY.....	9
IMPORTANCE OF THE INDUSTRY.....	9
PRODUCT LIFE CYCLES.....	10
<i>TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG</i>	11
DEVELOPMENT OF ANTIFUNGALS.....	11
DEVELOPMENT OF ANTIFUNGALS (CONTINUED).....	12
FDA-APPROVED ANTIFUNGALS.....	13
AZOLE ANTIFUNGALS.....	13
ECHINOCANDINS.....	13
POLYENES.....	14
ALLYLAMINES.....	14
MISCELLANEOUS ANTIFUNGALS.....	14
FUTURE DEVELOPMENTS.....	14
HUMAN CLINICAL DEVELOPMENT, 2007–2009.....	15
NEW DRUG ACTIVITY.....	16
<i>TABLE 2 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2007–2009</i>	17
<i>TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2007 AND 2012</i>	17

ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2007-2009	17
<i>TABLE 4 ACTIVE OR COMPLETED STUDIES, 2007-2009</i>	18
<i>TABLE 4 (CONTINUED)</i>	19
<i>TABLE 4 (CONTINUED)</i>	20

CHAPTER FOUR: INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL THERAPEUTICS.....	21
SCOPE OF APPLICATIONS: HUMAN HEALTHCARE.....	21
HUMAN FUNGAL INFECTIONS	22
RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS.....	23
<i>TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS</i>	24
<i>TABLE 5 (CONTINUED)</i>	25
FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS.....	25
Candidiasis	25
Some Basic Facts about Candida Infections.....	26
Some Basic Facts ... (Continued).....	27
Some Basic Facts ... (Continued).....	28
Cutaneous Candidiasis	29
Chronic Mucocutaneous Candidiasis	29
GI Tract Candidiasis.....	29
Respiratory Tract Candidiasis	29
Genitourinary Tract Candidiasis	30
Hepatosplenic Candidiasis	30
Systemic Candidiasis.....	30
Candidemia	30
Disseminated Candidiasis	31
Aspergillosis.....	32
Blastomycosis.....	33
Coccidioidomycosis	34
Cryptococcosis.....	35
Dermatophytosis.....	36
Dermatophytosis (Continued)	37
Histoplasmosis.....	38
Onychomycosis.....	39
Paracoccidioidomycosis.....	40
Pseudallescheriasis.....	41
Sporotrichosis	41
Zygomycosis	42
<i>TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES</i>	43
MORE RARE FUNGAL INFECTIONS AND DISORDERS	44
Literature Review.....	44
FUNGAL DRUG RESISTANCE	45
CURRENT DRUG RESISTANCE TOPICS: A GLOBAL VIEW	46

MDR SPECIES.....	47
MDR Species (Continued)	48
MDR Species (Continued)	49
Literature Review.....	50
<i>TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE</i>	<i>51</i>
STRATEGIES TO IMPROVE RESPONSE AND DECREASE	
MORTALITY	51
Literature Review.....	52
Literature Review (Continued)	53
CHAPTER FIVE: HUMAN ANTIFUNGAL AGENTS.....	54
<i>TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL</i>	
<i>CONSUMPTION BY PRODUCT TYPE, THROUGH 2014 (\$</i>	
<i>MILLIONS)</i>	<i>54</i>
CLASSES OF ANTIFUNGALS.....	54
ECHINOCANDINS.....	54
Literature Review.....	55
AZOLES.....	55
Literature Review.....	56
POLYENES	56
Literature Review.....	56
OTHER	57
<i>TABLE 9 GLOBAL ANTIFUNGAL PHARMACEUTICAL SALES:</i>	
<i>TRIAZOLES VS. OTHERS, THROUGH 2014 (\$ MILLIONS)</i>	<i>57</i>
<i>TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY</i>	
<i>CLASS/MECHANISM OF ACTION (%)</i>	<i>58</i>
<i>FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS</i>	
<i>(%)</i>	<i>58</i>
<i>TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE</i>	
<i>SALES PRICE PER DOSAGE, 2006*</i>	<i>59</i>
<i>TABLE 12 FUNGAL INFECTION AND TRADITIONAL</i>	
<i>PHARMACEUTICAL REMEDY</i>	<i>60</i>
<i>TABLE 13 TYPE OF CANDIDAL INFECTION AND</i>	
<i>PHARMACEUTICAL TREATMENT</i>	<i>61</i>
SIDE EFFECTS	<i>62</i>
<i>TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM</i>	
<i>ANTIFUNGAL PHARMACEUTICALS</i>	<i>63</i>
OTC ANTIFUNGAL PREPARATIONS	<i>64</i>
<i>TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF</i>	
<i>ADMINISTRATION</i>	<i>65</i>
NATURAL ANTIFUNGAL REMEDIES.....	65
NATURAL ANTIFUNGAL REMEDIES (CONTINUED)	66
TYPES OF NATURAL ANTIFUNGAL REMEDIES.....	67
Herbal Remedies.....	67
Enzyme-based Antifungal Agents.....	68

Enzyme-based Antifungal Agents (Continued)	69
<i>TABLE 16 COMMON NATURAL ANTIFUNGALS</i>	70
SUMMARY OF SELECTED NATURAL ANTIFUNGAL	71
Aloe.....	71
Literature Review	71
Curcumin	72
Literature Review	73
Mint.....	73
Literature Review	73
Wild Marjoram.....	74
Literature Review	74
Radish	75
Literature Review	75
Parnafungins	75
Literature Review	76
Ginseng	77
Literature Review	77
Walnut.....	77
Literature Review	78
Pau d'arco.....	78
Literature Review	78
Garlic.....	78
Literature Review	78
Grapefruit Seed	79
Literature Review	80
Olive Leaf.....	80
Literature Review	80
Goldenseal.....	80
Literature Review	81
Oregano.....	81
Literature Review	81
Tea Tree	82
Literature Review	82
NATURAL REMEDIES IN EARLIER DEVELOPMENT.....	83
Literature Review.....	83
Literature Review (Continued)	84
LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS	85
Specimen Examination.....	85
Cultures	85
Blood Serology	85
ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS.....	86
CAM Testing and Specialized Laboratories	86

Questionnaire for Symptoms	87
CHAPTER SIX: COMMON ENVIRONMENTAL FUNGI.....	88
MOLDS AND THE HUMAN ISSUES THEY PRODUCE	88
WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM.....	89
HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOLD	90
HEALTH RISKS DUE TO ... (CONTINUED).....	91
<i>TABLE 17 COMMON HEALTH SYMPTOMS BASED ON</i>	
<i>ENVIRONMENTAL FUNGI AND MOLDS</i>	92
<i>TABLE 18 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL</i>	
<i>MOLD REACTIONS</i>	92
<i>TABLE 19 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL</i>	
<i>MOLDS</i>	93
ENVIRONMENTAL MOLDS.....	93
ALTERNARIA	93
Literature Review.....	94
ASPERGILLUS	95
Literature Review.....	95
CLADOSPORIUM.....	96
Literature Review.....	96
PENICILLIUM.....	97
Literature Review.....	98
EUROTIUM.....	98
Literature Review.....	99
RHIZOPUS	99
Literature Review.....	99
MUCOR	100
Literature Review.....	100
GEOTRICHUM	101
Literature Review.....	101
FUSARIUM	102
Literature Review.....	102
STACHYBOTYRS	102
Literature Review.....	103
WALLEMIA.....	103
Literature Review.....	103
TRICHOTHECIUM.....	104
Literature Review.....	104
SCOPULARIOPSIS BREVICAULIS.....	104
Literature Review.....	104
SCYTALIDIUM DIMIDIATUM	105
Literature Review.....	105
TRICHODERMA	106
Literature Review.....	106
PAECILOMYCES VARIOTII	107

Literature Review.....	107
Literature Review (Continued)	108
CHAPTER SEVEN: GOVERNMENT REGULATORY AGENCIES AND	
PROFESSIONAL ASSOCIATIONS	109
GOVERNMENT REGULATIONS	109
FDA.....	109
<i>TABLE 20 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN</i>	
<i>SEGMENT FROM THE FDA, 1997–2009</i>	110
<i>TABLE 20 (CONTINUED)</i>	111
<i>TABLE 20 (CONTINUED)</i>	112
<i>TABLE 20 (CONTINUED)</i>	113
<i>TABLE 20 (CONTINUED)</i>	114
<i>TABLE 20 (CONTINUED)</i>	115
<i>TABLE 20 (CONTINUED)</i>	116
EPA	116
EPA (Continued).....	117
USDA	118
FOOD AND AGRICULTURE ORGANIZATION OF THE	
UNITED NATIONS	118
PROFESSIONAL ASSOCIATIONS	118
MEDICAL AND VETERINARY ASSOCIATIONS.....	118
AGRICULTURAL ASSOCIATIONS	119
OTHER ENVIRONMENTAL ASSOCIATIONS	119
CHAPTER EIGHT: ANTIFUNGAL COMPANIES.....	120
HUMAN HEALTHCARE	120
PHARMACEUTICAL MANUFACTURERS.....	120
<i>TABLE 21 MAJOR GLOBAL ANTIFUNGAL HUMAN</i>	
<i>PHARMACEUTICAL MANUFACTURERS</i>	121
<i>FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL</i>	
<i>MANUFACTURERS BY COUNTRY (%)</i>	121
<i>FIGURE 2 (CONTINUED)</i>	122
MAJOR PHARMACEUTICAL MANUFACTURER PROFILES	122
<i>TABLE 22 THE TOP 10 SALES VOLUMES OF ALL</i>	
<i>PHARMACEUTICAL PRODUCTS BY COUNTRY, 2008 (\$</i>	
<i>MILLIONS/%)</i>	123
<i>FIGURE 3 TOP 10 GROWTH RATES BY COUNTRY, 2008 (%)</i>	123
<i>TABLE 23 THE TOP 5 ANTIFUNGALS PRODUCING COMPANIES IN</i>	
<i>TERMS OF OVERALL SALES, 2008</i>	124
<i>TABLE 24 MAJOR GLOBAL ANTIFUNGAL SALES FORECAST,</i>	
<i>THROUGH 2014 (\$ MILLIONS)</i>	124
Astellas Pharma, Inc.	124
Bayer HealthCare.....	125
Enzon Pharmaceuticals.....	125

Galderma Pharma SA/Galderma SA	126
Gilead Sciences, Inc.	126
Medicis Pharmaceutical Corp.	126
Novartis International AG	127
Pfizer, Inc.	127
Taro Pharmaceutical Industries, Ltd.	128
Taro USA, Inc.	128
Teva Pharmaceutical Industries, Ltd.	128
OTC ANTIFUNGAL MANUFACTURERS	129
PHARMACEUTICAL OTC MARKET	129
<i>TABLE 25 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS</i>	
<i>AND PRODUCTS</i>	<i>130</i>
MAJOR PHARMACEUTICAL-BASED OTC MANUFACTURER	
PROFILES.....	130
Alva-Amco Pharmacal	130
Blaine Labs	130
Dartmouth Pharmaceuticals.....	131
Del Laboratories	131
Ganeden Biotech.....	131
Kramer Laboratories	132
Novartis International AG	132
Ortho McNeil	132
PEDiNOL Pharmacal, Inc.	133
Stiefel Laboratories	133
Tarmac Products.....	133
ALTERNATIVE OTC MANUFACTURERS	134
<i>TABLE 26 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS</i>	<i>134</i>
MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES.....	134
Aqua Flora	134
Crystal Star Herbal Nutrition	135
Enzymedica.....	135
Forest Herbs Research	135
Garden of Life	136
Michael's Naturopathic Programs	136
Nature's Plus	137
NOW Foods	137
Nutrition Now.....	137
ProSymbiotics	138
Pure Essence Laboratories	138
Rainbow Light.....	139
Renew Life	139
Solaray	139
Vitanica.....	140
CHAPTER NINE: ANTIFUNGAL INDUSTRY	141

ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE	141
ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT	141
<i>TABLE 27 NEW PRESCRIPTION ANTIFUNGALS, 2005–2009</i>	<i>142</i>
INCREASED TYPES OF TESTING	143
Need to Increase Use and Acceptance of Newer Drugs	143
SOME GENERAL STATISTICS	144
EXPERIMENTAL RESEARCH: CLINICAL TRIALS	
PERFORMED AND SELECTED PRECLINICAL AND <i>IN-</i>	
<i>VITRO</i> STUDIES.....	145
A GENERAL OVERVIEW OF NON-PHARMACEUTICAL	
ANTIFUNGAL TECHNOLOGIES.....	146
Laser and Photodynamic Therapy	146
Studies.....	147
Literature Review	147
mAbs.....	148
Diagnostics and Assays	148
Literature Review	149
Computer Modeling Technology	150
Literature Review	150
R&D SECTION: AN OVERVIEW OF NEW COMBINATIONS	150
Excluded Therapies	151
Included Therapies	151
NEW CLINICAL EXPERIMENTAL AND COMBINATION	
STUDIES, 2007–2009.....	152
<i>TABLE 28 NEW CLINICAL EXPERIMENTAL AND COMBINATION</i>	
<i>STUDIES, 2007–2009</i>	<i>153</i>
<i>TABLE 28 (CONTINUED)</i>	<i>154</i>
<i>TABLE 28 (CONTINUED)</i>	<i>155</i>
<i>TABLE 28 (CONTINUED)</i>	<i>156</i>
<i>TABLE 28 (CONTINUED)</i>	<i>157</i>
<i>TABLE 28 (CONTINUED)</i>	<i>158</i>
Human <i>In-vivo</i> Literature Review	158
Human <i>In-vivo</i> ... (Continued)	159
Human <i>In-vivo</i> ... (Continued)	160
Human <i>In-vivo</i> ... (Continued)	161
Preclinical Literature Review	162
Preclinical Literature Review (Continued).....	163
<i>In-vitro</i> Literature Review	164
<i>In-vitro</i> Literature Review (Continued).....	165
TRENDS IN CLASS USED AND ADMINISTRATION	
METHOD	166
<i>TABLE 29 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF</i>	
<i>ADMINISTRATION (%)</i>	<i>167</i>

<i>FIGURE 4 PHARMACEUTICAL ANTIFUNGALS ROUTE OF ADMINISTRATION (%)</i>	167
<i>TABLE 30 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ROUTE OF ADMINISTRATION, THROUGH 2014 (\$ MILLIONS)</i>	168
<i>UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS</i>	168
<i>Shifting Market from Prescription to OTC</i>	168
<i>TABLE 31 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS, 2005</i>	169
<i>TABLE 32 GLOBAL SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 (\$ MILLIONS)</i>	169
Market Demand for OTC Products	169
Market Demand for ... (Continued)	170
 CHAPTER TEN: PATENT ANALYSIS	171
PURPOSE OF A PATENT ANALYSIS.....	171
DUE CARE IN REVIEWING THE PATENT ANALYSIS	171
NEW ANTIFUNGAL PATENTS ISSUED	172
<i>TABLE 33 U.S. ANTIFUNGAL PATENT TRENDS, 1990–2009</i>	173
<i>TABLE 34 NEW U.S. ANTIFUNGAL PATENTS ISSUED, 2007–2009</i>	173
<i>TABLE 34 (CONTINUED)</i>	174
<i>TABLE 34 (CONTINUED)</i>	175
<i>TABLE 34 (CONTINUED)</i>	176
<i>TABLE 35 ASSIGNEES OF THREE OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS, 2007–2009</i>	176
<i>TABLE 36 U.S. PATENT TRENDS BY COUNTRY, 2007–2009 (NUMBER/%)</i>	176
<i>TABLE 36 (CONTINUED)</i>	177
<i>FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007–2009 (%)</i>	177
TRENDS IN PATENT APPLICATIONS	177
<i>TABLE 37 U.S. PATENT APPLICATION TRENDS, 2007–2009</i>	178
<i>FIGURE 6 U.S. ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2007–2009 (%)</i>	178
<i>TABLE 38 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007–2009</i>	179
<i>FIGURE 7 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007–2009 (%)</i>	179
<i>TABLE 39 NEW U.S. PATENT APPLICATIONS, 2007–2009</i>	180
<i>TABLE 39 (CONTINUED)</i>	181
<i>TABLE 39 (CONTINUED)</i>	182
<i>TABLE 39 (CONTINUED)</i>	183
<i>TABLE 39 (CONTINUED)</i>	184
<i>TABLE 39 (CONTINUED)</i>	185

<i>TABLE 40 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM OF ACTION, 2007–2009</i>	186
<i>TABLE 41 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007– 2009</i>	186
<i>FIGURE 8 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2007–2009 (%)</i>	187
<i>PATENT EXPIRATIONS</i>	187
<i>TABLE 42 PATENT EXPIRATIONS, 2006–2011</i>	188
APPENDIX	189
<i>TABLE 43 PHARMACEUTICAL COMPANIES</i>	189
<i>TABLE 43 (CONTINUED)</i>	190
<i>TABLE 43 (CONTINUED)</i>	191
<i>TABLE 43 (CONTINUED)</i>	192